Boosting of SARS-CoV-2 immunity in nonhuman primates using an oral rhabdoviral vaccine. Issue 15 (1st April 2022)

• Record Type: Journal Article
• Authors: Peng, Kah-Whye; Carey, Timothy; Lech, Patrycja; Vandergaast, Rianna; Muñoz-Alía, Miguel Á.; Packiriswamy, Nandakumar; Gnanadurai, Clement; Krotova, Karina; Tesfay, Mulu; Ziegler, Christopher; Haselton, Michelle; Sevola, Kara; Lathrum, Chase; Reiter, Samantha; Narjari, Riya; Balakrishnan, Baskar; Suksanpaisan, Lukkana; Sakuma, Toshie; Recker, Jordan; Zhang, Lianwen; Waniger, Scott; Russell, Luke; Petro, Christopher D.; Kyratsous, Christos A.; Baum, Alina; Janecek, Jody L.; Lee, Rachael M.; Ramachandran, Sabarinathan; Graham, Melanie L.; Russell, Stephen J.
• Is Part Of: Vaccine. Volume 40:Issue 15(2022)
• Page Start: 2342
• Page End: 2351
• Publication Date: 2022-04-01
• Subjects: SARS-CoV-2 -- Oral vaccine -- Rhabdovirus -- VSV -- Neutralizing antibodies -- T cells; Vaccines -- Periodicals; 615.372
• DOI: 10.1016/j.vaccine.2021.12.063
• Languages: English
• ISSNs: 0264-410X

Abstract

Abstract: An orally active vaccine capable of boosting SARS-CoV-2 immune responses in previously infected or vaccinated individuals would help efforts to achieve and sustain herd immunity. Unlike mRNA-loaded lipid nanoparticles and recombinant replication-defective adenoviruses, replicating vesicular stomatitis viruses with SARS-CoV-2 spike glycoproteins (VSV-SARS2) were poorly immunogenic after intramuscular administration in clinical trials. Here, by G protein trans-complementation, we generated VSV-SARS2(+G) virions with expanded target cell tropism. Compared to parental VSV-SARS2, G-supplemented viruses were orally active in virus-naive and vaccine-primed cynomolgus macaques, powerfully boosting SARS-CoV-2 neutralizing antibody titers. Clinical testing of this oral VSV-SARS2(+G) vaccine is planned.